Activating CD8+ T Cells by Pt(IV) Prodrug-Based Nanomedicine and aPD-L1 Antibody for Enhanced Cancer Immunotherapy
文献类型：期刊论文
| 作者 | Wang, Bin6,7; Zhou, Jingyu4,5,6; Li, Ruitong3; Tang, Dongsheng6,7; Cao, Zheng2; Xu, Chun1; Xiao, Haihua6,7 |
| 刊名 | ADVANCED MATERIALS
 |
| 出版日期 | 2024-02-23 |
| 页码 | 15 |
| ISSN号 | 0935-9648 |
| 关键词 | chemotherapy immunotherapy immunogenic cell death tumor immune microenvironment |
| DOI | 10.1002/adma.202311640 |
| 通讯作者 | Xiao, Haihua(hhxiao@iccas.ac.cn) |
| 英文摘要 | Recent years have witnessed substantial progress in cancer immunotherapy, specifically T cell-based therapies. However, the application of T cell therapies has been primarily limited to hematologic malignancies, with limited success in the treatment of solid tumors. The main challenge in treating solid tumor is immune escape, which is characterized by reduced antigenicity, diminished immunogenicity, and the development of suppressive tumor immune microenvironments. To address these obstacles and restore T cell-mediated anti-tumor responses, a novel nanoparticle formulation known as PRA@Oxa-c16 is developed. This innovative approach combines retinoic acid and Pt(IV) to specifically target and overcome immune escape. Notably, the therapeutic efficacy of PRA@Oxa-c16 primarily relies on its ability to induce anti-tumor T cell responses, in contrast to the cytotoxicity associated with conventional chemotherapeutic agents. When combined with an immune checkpoint blockade, anti-programmed death-ligand 1 antibody, PRA@Oxa-c16 effectively eliminates solid tumors and induces immune memory responses, which prevent tumor metastasis and recurrence. This promising approach holds great potential for enhancing the treatment of solid tumors with T cell-based immunotherapy. |
| WOS关键词 | TRANS-RETINOIC ACID ; THERAPY |
| 资助项目 | Chinese Academy of Sciences ; National Key Research & Development Program[2022YFC2603900] ; Central Government Guided Local Science and Technology Development Fund (Hebei)[216Z2601G] ; National Natural Science Foundation of China[22175189] |
| WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science ; Physics |
| 语种 | 英语 |
| 出版者 | WILEY-V C H VERLAG GMBH |
| WOS记录号 | WOS:001174635900001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309904]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Xiao, Haihua |
| 作者单位 | 1.Univ Queensland, Sch Dent, Brisbane, Qld 4006, Australia 2.Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA 3.Nankai Univ, Coll Chem, Dept Chem, Tianjin 300071, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China 5.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Mol Med, Hangzhou 310024, Zhejiang, Peoples R China 6.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 7.Chinese Acad Sci, Beijing Natl Lab Mol Sci, Lab Polymer Phys & Chem, Inst Chem, Beijing 100190, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Bin,Zhou, Jingyu,Li, Ruitong,et al. Activating CD8+ T Cells by Pt(IV) Prodrug-Based Nanomedicine and aPD-L1 Antibody for Enhanced Cancer Immunotherapy[J]. ADVANCED MATERIALS,2024:15. |
| APA | Wang, Bin.,Zhou, Jingyu.,Li, Ruitong.,Tang, Dongsheng.,Cao, Zheng.,...&Xiao, Haihua.(2024).Activating CD8+ T Cells by Pt(IV) Prodrug-Based Nanomedicine and aPD-L1 Antibody for Enhanced Cancer Immunotherapy.ADVANCED MATERIALS,15. |
| MLA | Wang, Bin,et al."Activating CD8+ T Cells by Pt(IV) Prodrug-Based Nanomedicine and aPD-L1 Antibody for Enhanced Cancer Immunotherapy".ADVANCED MATERIALS (2024):15. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。